NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02073682,Cancer Venous Thromboembolism (VTE),https://clinicaltrials.gov/study/NCT02073682,,COMPLETED,"The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.",YES,Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,DRUG: Edoxaban|DRUG: Dalteparin|DRUG: Low molecular weight heparin,"Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event, 12 months","Number of Participants With Adjudicated Major Bleeding Events While on Treatment, The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug)., 12 months|Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period, 12 months|Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period, 12 months|Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period, 12 months|Number of Participants With VTE-Related Death, 12 months|Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death, 12 months",,Daiichi Sankyo,,ALL,"ADULT, OLDER_ADULT",PHASE3,1046,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DU176b-D-U311|2014-004708-30,2015-07-16,2017-09-15,2017-09-15,2014-02-27,2018-10-24,2019-03-06,"Brandon, Florida, United States|Jonesboro, Georgia, United States|Detroit, Michigan, United States|Norfolk, Virginia, United States|Leuven, Vlaams-Brabant, Belgium|Saint-Etienne cedex 2, France|Debrecen, Hajdu-Bihar Megye, Hungary|Varese, Italy|Amsterdam, Netherlands","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/82/NCT02073682/Prot_SAP_000.pdf"
